AMRX PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

AMRX ▼ -7.88% at T+20d

LONG call ✗ call lost -7.88% · α vs SPY -11.04% · entry $12.82 → $11.81

Next anchor: T+60d in 5w

Last close $16.20 (close Jun 12) · +26.37% from $12.82 entry

Entry anchored
Apr 21, 03:59 PM ET
via Databento tick

T+1d

-1.33%

call -1.33% · α -0.93%

$12.65

settled 8w ago

T+5d

-0.55%

call -0.55% · α -0.60%

$12.75

settled 7w ago

T+20d

-7.88%

call -7.88% · α -11.04%

$11.81

settled 26d ago

T+60d

—

call — · α —

—

in 5w

Price Chart

Loading chart...

Executive Summary

Amneal Pharmaceuticals reported strong preliminary Q1 2026 results with revenue of $723M (4% YoY growth) and adjusted diluted EPS of $0.27, a 29% increase YoY and 59% above consensus of $0.17. The company raised full-year 2026 adjusted EPS guidance and announced a transformative $750M acquisition of Kashiv BioSciences to establish a leading biosimilars platform, positioning it to capture value from the upcoming $300B+ biologics LOE wave.

Key Financial Metrics

Guidance

$3.05 billion - $3.15 billion

raised

Gross Margin

44.3%

Actionable Insight

The combination of a strong earnings beat, raised guidance, and a strategically transformative acquisition positions AMRX for accelerated growth in biosimilars. Traders should monitor the shareholder vote and regulatory approvals for the Kashiv deal, and watch for further pipeline updates. The stock's reaction will likely focus on the long-term synergy potential and execution risk.

Key Facts

Preliminary Q1 2026 revenue: $723M (4% YoY growth)
Adjusted diluted EPS: $0.27 vs. consensus of $0.17 (59% beat)
GAAP diluted EPS: $0.19, also above consensus
Specialty segment revenue up 23% YoY to $133M driven by CREXONT® and BREKIYA®
Gross margin expanded 750 bps to 44.3% on strong product mix
Announced acquisition of Kashiv BioSciences for $750M ($375M cash + $375M equity) plus up to $350M in milestones
Raised 2026 full-year adjusted EPS guidance to $0.95–$1.05 (from $0.93–$1.03), now above consensus of $0.90)
Transaction expected to close in second half of 2026, subject to shareholder and regulatory approval

Financial Impact

Adjusted EPS of $0.27 beats consensus by $0.10 (59%), revenue of $723M beats by $2.5M. Full-year adjusted EPS guidance raised and now above consensus. Acquisition adds $400M–$500M in expected synergies.

epsrevenuegross_marginadjusted_ebitdaleverage

Risk Factors

Acquisition requires shareholder and regulatory approvals, creating execution risk
Preliminary financials are subject to change upon final audit
Integration risk from combining Kashiv’s operations

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3278749

6 reports for AMRX

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for AMRX — sortable, filterable
	Type				Now
Jun 11, 2026 3d ago	Institutional Cluster MIXED ★ 4/10	$15.72 awaiting T+20	awaiting T+20	—	$16.20 (+3.05%)
May 7, 2026 5w ago	Press Release BULLISH ★ 8/10	$13.20 $13.75	▲ +4.17%	▲ +4.14%	$16.20 (+22.73%)
Apr 22, 2026 7w ago	Press Release BULLISH ★ 9/10	$12.82 $11.81	▼ −7.88%	▼ −11.04%	$16.20 (+26.37%)
Apr 7, 2026 9w ago	Press Release NEUTRAL ★ 3/10	$12.71 $13.41	▲ +5.51%	▼ −3.04%	$16.20 (+27.46%)
Mar 25, 2026 11w ago	DEFA14A NEUTRAL ★ 3/10	$12.06 $12.52	▲ +3.81%	▼ −6.85%	$16.20 (+34.33%)
Feb 27, 2026 15w ago	8-K BULLISH ★ 8/10	$13.81 $11.85	▼ −14.19%	▼ −6.64%	$16.20 (+17.31%)

US Market Status

Market Closed — Opens in 5h 3m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access